Pressurized aerosol chemotherapy (PIPAC) for pancreatic cancer that has spread to the peritoneum
Official title: Phase I Trial of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma
Run by Northwell Health · NCT07253662 · Data updated 2026-11-12
This will try PIPAC (pressurized intraperitoneal aerosolized chemotherapy) with nab-paclitaxel in adults whose pancreatic adenocarcinoma has spread to the lining of the abdomen to see if it improves drug delivery and clinical outcomes.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Northwell Health Academic / other |
| Drugs / interventions | chemotherapy, doxorubicin |
| Locations | 1 site (New Hyde Park, New York) |
| Status | Recruiting |
| Started | January 11, 2026 |
| Main results expected | December 30, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | June 3, 2026 |
| Trial ID | NCT07253662 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed pancreatic adenocarcinoma and visible or biopsy-proven peritoneal metastasis, ECOG ≤2, adequate blood counts and organ function, and no contraindication to laparoscopy are ideal candidates.
✕Probably not a fit
Patients with widespread non-peritoneal metastases, poor performance status (ECOG >2), significant organ dysfunction, uncontrolled comorbidity, or who cannot undergo laparoscopy are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 1 interventional trial delivers low-dose chemotherapy as a pressurized aerosol (PIPAC) to the peritoneal cavity via laparoscopy in adults with pancreatic adenocarcinoma and peritoneal metastasis. The approach is intended to maximize local drug concentration and tissue penetration while minimizing systemic exposure, using nab-paclitaxel as the agent. Enrolled patients must have visible peritoneal disease, ECOG performance status of 0-2, and adequate organ function to undergo laparoscopy and chemotherapy. The study will focus on safety, tolerability, dose parameters, and preliminary signals of clinical or symptomatic benefit.
Why it matters
Potential benefit: If successful, this approach could deliver more chemotherapy directly to peritoneal tumor implants with lower systemic toxicity, potentially improving symptom control and survival.
How similar studies have gone: Early-phase and nonrandomized series of PIPAC in various cancers with peritoneal metastasis have shown feasibility and occasional tumor responses, but randomized evidence in pancreatic peritoneal metastasis is lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to understand and sign informed consent form * Age ≥18 years * Patient must have histologically confirmed pancreatic adenocarcinoma with either histologic confirmation or strong suspicion of peritoneal metastasis on cross sectional imaging * ECOG performance status ≤ 2 * Pre-treatment Laboratory Parameters: * Absolute neutrophil count (ANC) \> 1500/mm3 * Platelets \> 100,000/mm3 * Hemoglobin \> 9 g/dl * Serum total bilirubin \< 1.5 x upper limit of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN, unless patient is known to have chronic liver disease (hepatitis) in which case AST and ALT must be ≤ 5 x ULN. * Creatinine clearance (Ccr) \> 40 ml/min * No contraindications for a laparoscopy. * The peritoneal disease does not have to be measurable by RECIST 1.1 but needs to visible on cross sectional imaging or diagnostic laparoscopy. * For patients with a known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * Women of childbearing potential (WOCBP) and male patients with WOCBP partner must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 6 months after the PIPAC or last dose of chemotherapy in such a manner that the risk of pregnancy is minimized .-WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal. Post menopause is defined as: Amenorrhea ≥ 12 consecutive months without another cause or For women with irregular menstrual periods and on hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level \> 35 mIU/mL Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered of childbearing potential. Inclusion to proceed with PIPAC : Laparoscopy findings must meet all of the below criteria in order to proceed to PIPAC: * PIPAC access is feasible * There is room for aerosol therapy * There is no evidence of impending bowel obstruction * \< 5 L of ascites * Not a candidate for cytoreduction and HIPEC Exclusion Criteria: * Confirmed or suspected extra-peritoneal metastasis * Bowel obstruction requiring nasogastric tube, percutaneous endoscopic gastrostomy or exclusive total parenteral nutrition. * Life expectancy of less than 4 months. * Prior intra-abdominal aerosol chemotherapy * Previous anaphylactic reaction to the nab-paclitaxel drug used. * Intra-abdominal Ascites \>5L * Patients may not be receiving any other investigational agents. * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias, severe renal impairment, myelosuppression, or severe hepatic impairment. * Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system. * New York Heart Association (NYHA) Class 3 or 4; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months. * Exclusive total parenteral nutrition. * Pregnancy. Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Where it's running
-
Zuckerberg Cancer Center
New Hyde Park, New York, United States Recruiting
Study contacts
- Study coordinator: GI Trial Referral Team
- Email: gitrialreferral@northwell.edu
- Phone: (516) 734-8900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FAPi PET/CT scan for pancreatic ductal adenocarcinoma
This test uses a Gallium-68–labeled FAP inhibitor with PET/CT to see if it can detect tumor tissue and tumor-associated stroma in adults with biopsy-proven pancreatic ductal adenocarcinoma.
-
Hepatic artery infusion therapy for liver metastases after pancreatic/duodenal cancer surgery
This study tests whether delivering chemotherapy directly to the liver via a pump can help people with pancreatic or duodenal cancer that has spread mainly to the liver after surgery and prior chemotherapy.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
THE-0504 in patients with solid tumors
A first-in-human, dose-escalation study to see if THE-0504 is safe and tolerable in adults with solid tumors such as SCLC, CRC, GC, TNBC, and pancreatic cancer.
-
Planned surgery or focused local treatment after chemo for metastatic upper-GI adenocarcinoma with undetectable ctDNA
This test sees if adding planned surgery or local treatments after three months of chemotherapy helps people with metastatic upper-gastrointestinal adenocarcinomas who have undetectable ctDNA.
-
Preventing complications after high-risk Whipple (pancreatoduodenectomy) with hydrocortisone, octreotide, and a teres ligament patch
This tests whether giving hydrocortisone and octreotide around surgery plus placing a teres ligament patch can lower major complications after Whipple surgery in patients with a small pancreatic duct.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.